On Jul. 16, 2020, the Tufts Center for the Study of Drug Development reported that although regulatory approval time for new drugs in the U.S. had shortened, the time needed, on average, to complete clinical development of those drugs is lengthening by a greater amount, leading to longer times to develop and bring new drugs to market in the country.